https://pepsreview.com/articles/fda-warning-letters-unapproved-indian-branded-semaglutide PepsReview en 2026-10-14 FDA warning letter, unapproved semaglutide, online sellers, Indian generics, GLP-1 enforcement, misbranded drugs, peptide safety https://pepsreview.com/articles/retatrutide-poison-center-exposures-nearly-double PepsReview en 2026-10-14 retatrutide, poison center, bootleg peptides, FDA death reports, grey market GLP-1, adverse events, peptide safety https://pepsreview.com/articles/verdiva-bio-terminates-oral-glp-1-weight-maintenance-trial-strategy-pivot PepsReview en 2026-10-14 Verdiva Bio, VRB-101, ecnoglutide, oral GLP-1, weight maintenance, obesity clinical trials, peptide research https://pepsreview.com/articles/amylin-weight-loss-candidates-enter-late-stage-trials PepsReview en 2026-10-13 amylin, CagriSema, petrelintide, eloralintide, weight loss drugs, GLP-1, obesity treatment, FDA review https://pepsreview.com/articles/two-deaths-reported-fda-bootleg-retatrutide-scrutiny PepsReview en 2026-10-13 retatrutide, Reta, bootleg peptides, FDA adverse event reports, GLP-1, peptide safety, unapproved drugs, Eli Lilly https://pepsreview.com/articles/oral-semaglutide-fastest-weight-loss-drug-launch-on-record PepsReview en 2026-10-13 oral semaglutide, Wegovy pill, GLP-1 uptake, obesity treatment, prescription data, tirzepatide, real-world evidence, Annals of Internal Medicine https://pepsreview.com/articles/lilly-retatrutide-copycat-lawsuits-second-wave PepsReview en 2026-10-12 retatrutide, Eli Lilly, peptide lawsuits, black market peptides, unapproved GLP-1, FDA enforcement, research use only, peptide sourcing https://pepsreview.com/articles/glp-1-drugs-slow-biological-aging-clock-evidence PepsReview en 2026-10-12 GLP-1, semaglutide, tirzepatide, biological aging, epigenetic clocks, DunedinPACE, geroprotectors, clinical trial, longevity research https://pepsreview.com/articles/novo-nordisk-customers-live-lighter-fda-ad-enforcement PepsReview en 2026-10-12 Novo Nordisk, Wegovy, FDA untitled letter, GLP-1 advertising, direct-to-consumer ads, live lighter, drug marketing enforcement https://pepsreview.com/articles/us-glp-1-labels-still-lack-naion-warning-fda-review-pending PepsReview en 2026-10-12 NAION, GLP-1 vision loss, FDA label warning, Ozempic, Mounjaro, semaglutide, EMA safety review, drug labeling